Hyderabad-based Natco Pharma Ltd has filed an Abbrieviated New Drug Application (ANDA) for the generic version of Lapatinib ditosylate tablets in 250mg strength.
The company said it believed itself to be the first-to-file applicant for this product, which if true could lead to 180 days of marketing exclusivity.
The product, Glaxo's Tykerb tablets, is used for treatment of drug cancer and clocked revenues of $ 114 million in the United States last year.
Natco has partnered with Lupin for marketing the product, according to a company release.
On BSE, the company scrip is trading at Rs 267.95, up 2.7% over its previous close while the Sensex is up 0.81% at 12.40 pm.
